[The role of radiation therapy in the management of the Hodgkin's disease].
Radiation therapy has curative potential for patients with stage I-II disease, and five-year relapse-free survival rate in excess of 80% can be expected. Despite an advantage of chemotherapy combined with radiation therapy in improving relapse-free survival, no significant advantage has yet been demonstrated in allover survival. Patients with stage IIIA1 may also be treated radiation therapy alone with results of five-year survival rate of 53-60%. However, patients with stage IIIA2 should be treated with chemotherapy with or without radiation therapy combined.
Masaki
N
N
Dept. of Radiology, Osaka Univ. Med. School.
D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006689:Hodgkin Disease / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008479:Mediastinal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology / Q000628:therapy; D009367:Neoplasm Staging; D011879:Radiotherapy Dosage